• Home
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • Services
    • Proteomics
    • Genomics Transcriptomics
    • Flow Cytometry
    • Assay Development
    • Monoclonal Antibodies
    • Biobanking
    • OLINK Services
    • Biomarker Data Analyses
  • R&D
  • Products
    • NEUROLINCS
    • FIMICS
    • BIOPRED
    • IVD Products
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
    • Your Customized Kit
  • Quality
  • Investors
    • Financial Management
    • Financial Data
    • Shareholders
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
  • Careers
Contact
Firalis
  • Home
  • About
  • Services
  • Products
  • R&D
  • Quality
  • Investors
  • Media
FIRALIS obtains ISO 14001 International Quality Standard !

FIRALIS obtains ISO 14001 International Quality Standard !

Huningue, France, June 27, 2022

 

Firalis S.A. is pleased to announce the obtaining of the ISO 14001 certification for the development, production and sales of in vitro diagnostic tests, as well as for the storage and analysis of samples. ISO 14001 is an international standard that provides specific requirements for an effective Environmental Management System (EMS), enhancing performance to protect the environment and increasing the ability to meet supplier requirements.

 

As another major step took forward by Firalis, promoter of continuous improvement and committed to serve the biopharmaceutical industry with the highest quality standards that exist, ISO 14001 takes its place within the Quality Management System of Firalis, next to ISO 9001, ISO 13485, NFS S96-900 and others (www.firalis.com/quality) as the most respected environmental systems standard.

 

***

 

About FIRALIS S.A.

Firalis S.A. is a pioneering biotechnology company that offers CRO services and develops diagnostic products through discovery, development and regulatory qualification of innovative biomarkers for precision medicine, to improve prognosis of disease outcomes and therapeutic decisions. Firalis develops RUO (Research-Use-Only) and IVD (In-Vitro Diagnostic) kits, within the fields of cardiovascular diseases, neurodegenerative disorders (Alzheimer), inflammatory/autoimmune diseases and using cutting-edge technology platforms, with an exceptional team of experts and very high-quality industry standards.

Press contact : press{a}firalis.com

11.07.2022

Contact Firalis

Firalis Group

© Copyright 2020 all rights reserved. 

The company logos, products and service marks are trademarks or registered trademarks of Firalis.

-----------------------------------------------------------------------------------------------------------------------

Information addressed to health professionals. The products presented on this site are for professional use only and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

-----------------------------------------------------------------------------------------------------------------------

Headquarter : 17 Rue du Fort 68330 Huningue FRANCE